Customized Apple iPad Air Enhances Doctor-Patient Interactions in Clinical Trials
BBK Worldwide (BBK), the global leader in patient recruitment, announced today Study eBinder 3.0, the latest generation of its novel clinical trial management tool. The release of this product builds upon the success of earlier models by offering a dramatically more customized and tailored tablet experience for on-the-go study teams. Utilizing BBK's patented TrialCentralNet (TCN®) patient recruitment portal, Study eBinder 3.0 ensures compliance by providing more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff.
"The conversation is no longer about tech adoption as today's tablet culture continues to widen," said Matt Kibby, principal, technology and innovation, BBK Worldwide. "Thirty-five percent of Americans own tablets and that number is growing. BBK was the first to translate tablets into the clinical R&D industry, ensuring clinical trial management stays top of mind."
BBK's Study eBinder 3.0 is fully customizable for both the sponsor's brand and content. With an ultimate goal of enrolling studies sooner than ever before, the metrics-driven resource is effortless to implement.
"Sites are quick to adopt this new technology," said Lucas Garmon, media strategist, BBK Worldwide. "Universal implementation of online resources across devices guarantees individuals have the most critical information at all times. From coordinating study appointments to reviewing the informed consent with patients, we have seen sites begin to rely on their ability to manage studies remotely."
Study eBinder 3.0 is also available in a restricted sponsor view, as well as a patient view, which includes condition-specific information, tips for study participation, and customized retention tools. To learn more, visit shop.BBKWorldwide.com/products/ebinder-study-ipads.
About BBK Worldwide (bbkworldwide.com)
Founded in 1983, BBK Worldwide is the recognized global leader in patient recruitment. The company is renowned for accelerating time to market for new and improved medicines and treatments. Through its partner companies, TCN Technologies and Agency320, BBK offers the industry the most sophisticated technology, creative, and media services. BBK is certified as a Safe Harbor company.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.